Physician-scientist, Lymphoma oncologist @DanaFarber | Tweets are my own and not medical advice. #Lymphoma
Boston, MA
Joined October 2019
- Tweets24
- Following311
- Followers209
- Likes193
Erin Parry, MD PhD retweeted
Excited to share our latest publication from the Lili Wang lab! by Prajish Iyer et al.🌟 MGA deletion drives Richter’s transformation by modulating mitochondrial OXPHOS, highlighting new therapeutic avenues. @DanilovLab @CllSociety
science.org/doi/10.1126/scit…
Erin Parry, MD PhD retweeted
#AACRlymph24 cochair Ari M. Melnick, Sandrine Roulland, and Erin M. Parry discussed "Lymphoma Clonal Precursors and Transformation" in a plenary session at the Fourth AACR International Meeting on Advances in Malignant Lymphoma. @LabMelnick @SRoulland @ErinMParry
Erin Parry, MD PhD retweeted
🔬Are you an early-career researcher ready to take the next step in your research career? Apply for ASH & @EHA_Hematology's #TRTH program! Read the testimonials to see what past participants had to say about their experiences! Apply by June 20: ow.ly/GoW250RJTko
#hematology
Erin Parry, MD PhD retweeted
At #ASH23, Reid Merryman, MD @DanaFarber reveals results from a pilot study that uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (#DLBCL).
Press release: ms.spr.ly/6013iTO1S
Erin Parry, MD PhD retweeted
#ASH23 - Abstract 223
Outstanding presentation by @Dr_KatieM 👏🏻👏🏻👏🏻
Response to axi-cel is associated with:
✅The presence of > 0.5% circulating B-cells at baseline
✅Higher ALC/AMC at baseline
✅Enrichment of clonally expanded
CD8+ TEM cells in IP
#CARTcell
Erin Parry, MD PhD retweeted
@inhyeahn from @DanaFarber presenting at #iwcll2023 on one of the largest datasets ever reported for BTKi resistance mechanisms in CLL @iwCLL
Erin Parry, MD PhD retweeted
Congratulations to Dr. Susan O’Brien (@UCIrvineHealth) and Dr. Catherine Wu (@DanaFaber), recipients of the iwCLL Binet-Rai Medals for outstanding contributions to CLL research at #iwCLL2023
Had a great time at #iwCLL2023 sharing our work @RomainGuieze @lesh_lab @getz_lab Stilgenbauer and Wu in an amazing genomics session! Fascinating talks by Cindy Hahn @FerranNadeu @PaulineRobbe
@iwCLL2023 So many great contributions to the #Richter biology this year ! Bravo to @ErinMParry and @FerranNadeu for such great talks !
Congrats Elisa!
#AndJustLikeThat 🌟the ten Hacken lab is officially live from @WeillCornell NYC! 🌟
Join me in this new exciting adventure if you are interested in understanding chronic lymphocytic leukemia and Richter’s syndrome through mouse modeling (and more!). Recruiting at all levels!
Erin Parry, MD PhD retweeted
The story behind Venetoclax, a new cancer therapy, started nearly 40 years ago. How it went from the discovery of a protein to a game-changing cancer drug is a story of persistence and momentum and the first episode of season two of the Unraveled podcast. podcasts.apple.com/us/podcas…
Erin Parry, MD PhD retweeted
During an early morning session here at #ASH22, there’s an overflow crowd for @DanaFarber Caron Jacobson’s, MD, MMSc, presentation on her findings from her investigator-initiated study of CAR T-cell therapy for CNS lymphoma. There’s not an empty seat in the ballroom.
Erin Parry, MD PhD retweeted
This was all only possible because of the study’s lead investigator and my incredible mentor @DrMDavids. Many, many thanks to him for the generous opportunity to present these results yesterday! #ASH22 @DanaFarber @DanaFarberNews
Presenting her findings to a packed auditorium, @DanaFarber Christine Ryan, M.D. explains how a triple regimen of AVO was shown highly effective in patients with high-risk forms of Chronic Lymphocytic Leukemia. #ASH22
Erin Parry, MD PhD retweeted
In vivo modeling of #CLL transformation to #Richtersyndrome reveals convergent evolutionary paths and therapeutic vulnerabilities, by @etenhacken et al.
bit.ly/3uxoFRe
@DanaFarberNews @DanaFarber @harvardmed #chroniclymphocyticleukemia
Erin Parry, MD PhD retweeted
1/Very excited to see this out online at @BCD_AACR!
Check out our novel mouse models reflective of chronic lymphocytic leukemia (CLL) transformation into Richter’s syndrome achieved via combinatorial CRISPR-Cas9 gene editing!
aacrjournals.org/bloodcancer…
Erin Parry, MD PhD retweeted
@etenhacken has developed a new model for Richter's syndrome, the transition of #CLL to a high-grade lymphoma, which is the perfect context to study clonal evolution using #mtDNA mutations. Check out her brand new @BCD_AACR paper also released today! /4
aacrjournals.org/bloodcancer…
Erin Parry, MD PhD retweeted
Finally, we also saw mtDNA mutations that were further enriched in the Richter's model after transplant into a recipient animal. This demonstrates that - like in human - mitochondrial DNA mutations in mice can be dynamic markers of distinct subclones and differential chromatin./9
Erin Parry, MD PhD retweeted
🐭 Can mitochondrial DNA mutations track lineage in murine cancer models❓ Together w/ @etenhacken plus the mtDNA experts @LeifLudwig and @CalebLareau we investigated this question with mtscATAC-seq using Elisa's #CLL and #RS models. Out now in @CR_AACR./1
aacrjournals.org/cancerres/a…
